Literature DB >> 18986663

Protection against lethal challenge by Ebola virus-like particles produced in insect cells.

Yuliang Sun1, Ricardo Carrion, Ling Ye, Zhiyuan Wen, Young-Tae Ro, Kathleen Brasky, Anysha E Ticer, E Ellen Schwegler, Jean L Patterson, Richard W Compans, Chinglai Yang.   

Abstract

Ebola virus-like particles (VLPs) were produced in insect cells using a recombinant baculovirus expression system and their efficacy for protection against Ebola virus infection was investigated. Two immunizations with 50 microg Ebola VLPs (high dose) induced a high level of antibodies against Ebola GP that exhibited strong neutralizing activity against GP-mediated virus infection and conferred complete protection of vaccinated mice against lethal challenge by a high dose of mouse-adapted Ebola virus. In contrast, two immunizations with 10 microg Ebola VLPs (low dose) induced 5-fold lower levels of antibodies against GP and these mice were not protected against lethal Ebola virus challenge, similar to control mice that were immunized with 50 microg SIV Gag VLPs. However, the antibody responses against GP were boosted significantly after a third immunization with 10 microg Ebola VLPs to similar levels as those induced by two immunizations with 50 microg Ebola VLPs, and vaccinated mice were also effectively protected against lethal Ebola virus challenge. Furthermore, serum viremia levels in protected mice were either below the level of detection or significantly lower compared to the viremia levels in control mice. These results show that effective protection can be achieved by immunization with Ebola VLPs produced in insect cells, which give high production yields, and lend further support to their development as an effective vaccine strategy against Ebola virus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18986663      PMCID: PMC2657000          DOI: 10.1016/j.virol.2008.09.020

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  36 in total

1.  Analysis of the murine leukemia virus R peptide: delineation of the molecular determinants which are important for its fusion inhibition activity.

Authors:  C Yang; R W Compans
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 2.  Filovirus assembly and budding.

Authors:  Bettina Hartlieb; Winfried Weissenhorn
Journal:  Virology       Date:  2006-01-05       Impact factor: 3.616

3.  Expression and self-assembly of empty virus-like particles of hepatitis E virus.

Authors:  T C Li; Y Yamakawa; K Suzuki; M Tatsumi; M A Razak; T Uchida; N Takeda; T Miyamura
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections.

Authors:  Dana L Swenson; Kelly L Warfield; Diane L Negley; Alan Schmaljohn; M Javad Aman; Sina Bavari
Journal:  Vaccine       Date:  2005-04-27       Impact factor: 3.641

Review 5.  An introduction to Ebola: the virus and the disease.

Authors:  C J Peters; J W LeDuc
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

6.  Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP.

Authors:  Takeshi Noda; Hiroshi Sagara; Emiko Suzuki; Ayato Takada; Hiroshi Kida; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.

Authors:  M Bray; K Davis; T Geisbert; C Schmaljohn; J Huggins
Journal:  J Infect Dis       Date:  1998-09       Impact factor: 5.226

8.  Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients.

Authors:  M A Bwaka; M J Bonnet; P Calain; R Colebunders; A De Roo; Y Guimard; K R Katwiki; K Kibadi; M A Kipasa; K J Kuvula; B B Mapanda; M Massamba; K D Mupapa; J J Muyembe-Tamfum; E Ndaberey; C J Peters; P E Rollin; E Van den Enden; E Van den Enden
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

9.  Ebola virus-like particles protect from lethal Ebola virus infection.

Authors:  Kelly L Warfield; Catharine M Bosio; Brent C Welcher; Emily M Deal; Mansour Mohamadzadeh; Alan Schmaljohn; M Javad Aman; Sina Bavari
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

10.  Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses.

Authors:  Sina Bavari; Catharine M Bosio; Elizabeth Wiegand; Gordon Ruthel; Amy B Will; Thomas W Geisbert; Michael Hevey; Connie Schmaljohn; Alan Schmaljohn; M Javad Aman
Journal:  J Exp Med       Date:  2002-03-04       Impact factor: 14.307

View more
  47 in total

1.  Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice.

Authors:  Wenfang Li; Ling Ye; Ricardo Carrion; Gopi S Mohan; Jerritt Nunneley; Hilary Staples; Anysha Ticer; Jean L Patterson; Richard W Compans; Chinglai Yang
Journal:  J Infect Dis       Date:  2015-04-14       Impact factor: 5.226

2.  Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.

Authors:  Nicholas J Lennemann; Andrew S Herbert; Rachel Brouillette; Bethany Rhein; Russell A Bakken; Katherine J Perschbacher; Ashley L Cooney; Catherine L Miller-Hunt; Patrick Ten Eyck; Julia Biggins; Gene Olinger; John M Dye; Wendy Maury
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

3.  Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity.

Authors:  Helena Müller; Sarah Katharina Fehling; Jens Dorna; Richard A Urbanowicz; Lisa Oestereich; Yvonne Krebs; Larissa Kolesnikova; Martin Schauflinger; Verena Krähling; N'Faly Magassouba; Elisabeth Fichet-Calvet; Jonathan K Ball; Andreas Kaufmann; Stefan Bauer; Stephan Becker; Veronika von Messling; Thomas Strecker
Journal:  NPJ Vaccines       Date:  2020-08-04       Impact factor: 7.344

4.  Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses.

Authors:  Mallory Willet; Drishya Kurup; Amy Papaneri; Christoph Wirblich; Jay W Hooper; Steve A Kwilas; Rohan Keshwara; Andrew Hudacek; Stefanie Beilfuss; Grit Rudolph; Elke Pommerening; Adriaan Vos; Andreas Neubert; Peter Jahrling; Joseph E Blaney; Reed F Johnson; Matthias J Schnell
Journal:  J Infect Dis       Date:  2015-06-10       Impact factor: 5.226

Review 5.  Advances in virus-like particle vaccines for filoviruses.

Authors:  Kelly L Warfield; M Javad Aman
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

6.  Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge.

Authors:  Zhiyuan Wen; Ling Ye; Yulong Gao; Lei Pan; Ke Dong; Zhigao Bu; Richard W Compans; Chinglai Yang
Journal:  Antiviral Res       Date:  2009-09-20       Impact factor: 5.970

7.  An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.

Authors:  Reed F Johnson; Drishya Kurup; Katie R Hagen; Christine Fisher; Rohan Keshwara; Amy Papaneri; Donna L Perry; Kurt Cooper; Peter B Jahrling; Jonathan T Wang; Jan Ter Meulen; Christoph Wirblich; Matthias J Schnell
Journal:  J Infect Dis       Date:  2016-07-24       Impact factor: 5.226

8.  A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence.

Authors:  Amy B Papaneri; Christoph Wirblich; Jennifer A Cann; Kurt Cooper; Peter B Jahrling; Matthias J Schnell; Joseph E Blaney
Journal:  Virology       Date:  2012-08-11       Impact factor: 3.616

9.  Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola.

Authors:  Devon J Shedlock; Jenna Aviles; Kendra T Talbott; Gary Wong; Stephan J Wu; Daniel O Villarreal; Devin Jf Myles; Maria A Croyle; Jian Yan; Gary P Kobinger; David B Weiner
Journal:  Mol Ther       Date:  2013-05-14       Impact factor: 11.454

10.  Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.

Authors:  Amy B Papaneri; Christoph Wirblich; Kurt Cooper; Peter B Jahrling; Matthias J Schnell; Joseph E Blaney
Journal:  Vaccine       Date:  2012-08-08       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.